Maridebart Cafraglutide for overweight

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Obesity

Why this status

  1. 23 May 2025: Trial registered, NCT06987695
  2. 13 Jun 2025: Trial started, NCT06987695

The trials

NCT06987695: Efficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease

State
Under way
Phase
Phase 3
People
279 taking part
Started
13 Jun 2025
Primary completion
27 Apr 2027
Arms
Maridebart Cafraglutide High Dose, Maridebart Cafraglutide Medium Dose, Maridebart Cafraglutide Low Dose
Results
None posted
  1. 23 May 2025: Trial registered
  2. 13 Jun 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.